Clinical Trial Detail

NCT ID NCT02752035
Title A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.

acute myeloid leukemia



Azacitidine + Gilteritinib


Age Groups: senior adult

Additional content available in CKB BOOST